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Abstract
Molecular diagnosis of cystic fibrosis is based on the detection of mutation in the CFTR
gene, identified in 1989. During the past 20 years, thanks to evolutions of diagnostic
techniques, our knowledge of mutation spectrum and pathophysiological mecha‐
nisms involved in the disease has significantly improved. Sanger sequencing and
quantitative methods greatly contributed to the identification of the 2,000 sequence
variations reported worldwide in CFTR. We are now entering the new technological
age with the generalisation of Next Generation Sequencing (NGS) technologies in
diagnostics laboratories. These high throughput approaches allow scanning for the
entire CFTR locus, including deep intronic regions, and in parallel other candidate
genes that possibly influence the clinical evolution of patients. However, this powerful
technology poses new challenge in test interpretation. In this chapter, we review the
current and new technologies used in molecular diagnostics of cystic fibrosis,
particularly NGS approaches. We also present current and new bioinformatics tools
available for the interpretation of variants and in vitro/ex vivo and in vivo techniques
that can be used to improve the characterization of the functional impact of CFTR
variations.
Keywords: Next generation sequencing, CFTR, sequence variations, interpretation,
functional characterization
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1. Introduction
The autosomal recessive mode of inheritance of Cystic Fibrosis (CF) was suggested by
Andersen and Hodges in 1945 when they described this disease as a pathological entity.
Since the discovery of the CFTR gene (and the predicted protein cystic fibrosis transmembrane
conductance regulator) in 1989 [1], close to 2, 000 variations have been identified on this locus.
CFTR gene studies represent one of the most frequent genetic analyses routinely performed
worldwide, either to confirm the clinical diagnosis of CF or CFTR-related disorders (CFTR-
RDs), or to offer carrier testing, prenatal or pre-implantation genetic diagnosis.
The most common severe mutation, p.Phe508del, is found in approximately 70% of CF alleles
of European descent (therefore it is present in 49% of homozygous and 42% of compound
heterozygous CF patients), with significant variations depending on ethnicities [2]. There is a
clear decreasing northwest to southwest gradient in p.Phe508del frequency across Europe.
Only four other mutations represent more than 1% of CF cases: p.Gly542*, p.Gly551Asp,
p.Asn1303Lys, and p.Trp1282*. All other mutations are rare and many are private, only
detected within a single family.
Figure 1. Two models for the classification of CFTR variants: (1) Functional: five classes of defective CFTR protein [3, 4,
5]; and (2) Clinical: four classes based on phenotypic expression in patients [6].
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Therefore, a good knowledge of CFTR diseases and their molecular pathology is required
when choosing tools and strategy and when interpreting results. Organization of regional or
national networks of specialist clinical and molecular genetic laboratories is needed. Two
models for the classification of sequence alterations have been proposed (Figure 1): (1)
depending on their molecular impact on the CFTR chloride channel, which requires in
vitro/in vivo functional assays, now less used due to the difficulty in accurately classifying the
new reported variants [3, 4] or (2) by their clinical consequences on patients based on detailed
and prospective clinical evaluation of patients associated with molecular findings [5].
However, even if the most severe mutations were studied in vitro, mild mutations or variants
of unknown (clinical) significance (VUCs or VUS) were barely analysed. Thus, only one third
of CFTR variations are functionally classified. Finally, in CF, as in other genetic diseases, new
molecular diagnosis techniques such as Next Generation Sequencing (NGS) allow the analysis
of the whole CFTR locus (including deep intronic regions) but increase the number of VUCS
reported on patients.
Therefore, geneticists and clinicians have to combine CFTR epidemiological databases,
functional in vitro/in vivo analysis and exhaustive clinical data to perform pertinent genotype/
phenotype correlations in patients in order to provide appropriate genetic counselling to
families.
2. Technical aspects of molecular diagnosis
The CFTR genetic testing strategy depends on the clinical and familial context and is classically
performed step by step, as recommended [7]. As shown in Figure 2, tests are carried out in
various situations, including confirmation of a clinical diagnosis, prenatal diagnosis (familial
context or foetal suspicion of CF) and carrier screening.
A wide range of techniques is still used to identify CFTR gene sequence variations (presented
in Table 1) and there is no gold standard or preferred method for routine testing. However,
laboratories should be aware of the limitations of their chosen method (e.g. some mutations
are not identified). Moreover, assay performance should always be verified before diagnostic
use, even though commercial kits are CE-marked in vitro diagnostic devices (IVDD). In the
perspective of accreditation (expected in France in 2020 for hospital diagnostic laboratories),
all methods used in molecular biology should be validated before diagnostic use, notably by
comparison with a reference method (Sanger sequencing for Single Nucleotide Variations and
quantitative PCR for Copy Number Variations detection). This technical validation should be
undertaken for NGS in the step 1 and 2 diagnosis.
Undetected CFTR mutations may lie within the introns or regulatory regions, which are not
routinely explored but that will be soon analysed by NGS. Comparison between NGS and
reference methods for the identification of CFTR variants on these unexplored regions will be
a challenge.
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Figure 2. CF molecular diagnosis: a step-by-step strategy (modified from [7]). NBS: newborn screening; SNV: Single
Nucleotide Variation; CNV: Copy Number Variation; MLPA: Multiplex Ligation-dependent Probe Amplification.
2.1. Current techniques to detect CFTR variants
2.1.1. Screening techniques (Step 1)
These approaches consist of genotyping a panel of frequent CF mutations using commercial
kits (Table 1) that classically cover more than 80% of CF known mutations in European
populations. Additional search for mutations specific to certain regions or ethnicities (fre‐
quency higher than 1% of CF alleles in the targeted population) completes the analyses.
Data on disease and carrier frequencies or mutation frequencies in various populations are
available in the WHO report [8] and should be accurately known and used by laboratories.
For many patients carrying CF-causing mutations included in commercial panels, CFTR
molecular analysis generally stops at this step. There is no need for additional studies, except
the confirmation of mutations by a second method, as recommended by international guide‐
lines for genetics diagnosis.
2.1.2. Scanning techniques (Step 2)
The high heterogeneity of CFTR mutations in CF and CFTR-RD populations makes the
complete molecular screening of the 27 exons and parts of the regulatory regions (5’UTR,
3’UTR and partial intronic regions) essential.
Therefore, the analysis of the CFTR locus can be performed as follows:
Cystic Fibrosis in the Light of New Research204
• To detect SNV: scanning the 27 exons of the CFTR gene, intronic boundaries and four
intronic regions with reported deep intronic mutations [9-12] and a part of the promoter.
As an example, one can use Sanger sequencing with Single Condition Amplification Primers
(SCAP) technique [13].
• To detect CNV (large CFTR rearrangements): scanning of exon by multiplex fluorescent
quantitative PCR (Multiplex Ligation-dependent Probe Amplification or MLPA) or array-
CGH [14].
These robust methods allow the detection of more than 97% of CFTR mutations involved in
CF.
2.1.3. Advantages and limits
Classical screening or scanning methods used to detect mutations (in step 1 and 2) have high
specificity and sensitivity (Table 1). Older techniques such as RFLP (restriction fragment length
polymorphism), DGGE (denaturing gradient gel electrophoresis) or DHPLC (denaturing high
performance liquid chromatography) were widely used in the past 20 years but were difficult
to set up and showed inconstant performance. They have been progressively replaced by easy-
to-use commercial kits, more appropriate for larger sample series. These kits allow PCR
multiplexing and thus enable the detection of the most common CF mutations in one reaction.
Sanger sequencing and quantitative PCR are the most effective to identify unknown mutations.
However, all these classical methods are labour-intensive and time-consuming.
Method name Mutations detected Advantages Limits
Screening (step 1)
Reverse dot blot hybridization Up to 20 mutations per multiplex
Appropriate for large series
High specificity
Cost effective
Partial hybridization if SNP on
probe
ARMS (amplification refractory
mutation system) Up to 50 mutations
Primer Design difficult
Need of high agarose gel quality
OLA (Oligonucleotide ligation
assay) 32 mutations (Abbott kit)
Partial hybridization if SNP on
probe
NGS 139 to 166 CFTR variants Need of sufficient coverageIn development (Illumina)
Scanning (Step 2)
HRM (High Resolution Melting
curve analysis) Heterozygous variants
Appropriate for large series (e.g.
epidemiological studies)
Exon by exon
Need of positive cases
Not adapted for homozygous
variants
Sanger Sequencing All sequenced bases Close to 100% sensitivity Expensive methodCan not detect CNV
Quantitative fluorescent multiplex
PCR
Deletions, duplications,
insertions Simple and rapid
False positive if SNP on probe
Performance dependent on DNA
quality
NGS (used for step 3) All sequenced bases Appropriate for large seriesCost effective
Need of sufficient coverage
In development (Illumina)
Table 1. Overview, advantages and limits of screening and scanning techniques used in molecular genetics diagnosis
(adapted from [7])
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2.2. Next Generation Sequencing (NGS)
2.2.1. Principle of NGS technologies
The development of Next Generation Sequencing (NGS) or Massively Parallel Sequencing
(MPS) technologies with an immense capacity (up to 1 Terabase (Tb) of data per run with the
HiSeq2500 system, Illumina) is a major technical progress in the field of human genetics. Since
2004, three principal NGS platforms have been commercially available, including (i) 454 GS
FLX & GS junior from Roche (ii) Genome Analyzer, HiSeq & MiSeq from Illumina and (iii)
SOLiD & Ion Torrent PGM from Life Technologies-Applied Biosystems (AB) [15]. These
technologies differ in terms of sample library preparation workflow, enabling sequencing on
any of the current NGS sequencers (e.g. Illumina, Life technologies, Roche). Since late 2004,
three principal NGS firms developed sequencers commercially available (listed in Table 2).
454 pyrosequencing is a sequencing-by-synthesis method that measures the release of
inorganic pyrophosphate upon incorporation of nucleotides, by converting it into luciferase
chemiluminescent signals using a series of enzymatic reactions. Ion Torrent semiconductor
technology is also based on a sequencing-by-synthesis approach but measures pH changes
(instead of light) induced by the release of hydrogen ions as nucleotides are incorporated.
SOLiD technology is a ligation-based sequencing system. DNA ligase is used to identify the
nucleotide present at a given position in a DNA sequence; each base is read twice, which
increases accuracy, even for homopolymeric regions. Base detection uses a mixture of labelled
oligonucleotides, which queries the input strand with ligase. In Illumina system, clonal
amplification is performed using a process termed ‘bridge amplification’ followed by two basic
steps, initial priming and extending of the single-stranded, single-molecule template and
bridge amplification of the immobilized template with immediately adjacent primers to form
clusters. For sequencing, only dye-labelled terminators are added; then the sequence at that
position is determined for all clusters; next, the dye is cleaved and another round of dye-
labelled terminators is added.
Platform GAII, HiSeq &MiSeq Ion Torrent SOLiD GS FLX & GS Junior
Methodology Sequencing by synthesis(Reversible termination) Sequencing by synthesis Sequencing by Ligation
Sequencing by synthesis
(Pyrosequencing)
Loading
Adaptors on template
DNA bind high density
primers across surface of
slide
Adaptors on template
DNA bind primers on
beads, one molecule per
bead
Adaptors on template DNA
bind primers on beads, one
molecule per bead
Adaptors on template DNA
bind primers on beads, one
molecule per bead
Clonal amplification Bridge PCR: Surfacearray on flow cell
Emulsion PCR: clusters on
beads
Emulsion PCR: clusters on
beads
Emulsion PCR: clusters on
beads
Parallelisation Random array on flowcell Beads loaded on a chip
Beads bonded to high
density glass slide
Beads loaded onto high
density plate
Detection Fluorescence H
+ ions (sensitive pH
meter) Fluorescence Light (luciferase)
Table 2. Overview of the main NGS technologies
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2.2.1.1. Target enrichment
Targeted re-sequencing isolates genomic regions of interest in a sample library, allowing to
focus efficiently and cost-effectively on a small subset of the genome, such as an exome, a
particular chromosome, a set of genes or a region of interest such as a whole gene. Two main
strategies can be envisioned: capture [16, 17] or amplification relevant genomic DNA [18-20]
as shown in Table 3.
Strategy Capture/hybridisation-based method Amplicon-based method
Methods HaloPlex
SureSelect
(Agilent) /SeqCap
(NimbleGen)
Nextera (Illumina)
Microdoplet
(RainDance
Technologies)
Multiplex PCR
(AmpliSeq, Life
Technology &
TrueSeq,
Illumina)
Long-Range PCR
Qiagen & "home"
design
Main steps
Restriction enzyme
digestion
Sonication/
nebulisation
Tagmentation with
transposon Sonication
PCR
amplification PCR amplification
Probe hybridisation
PCR amplification
+ probe
hybridisation
PCR amplification
+ probe
hybridisation
Sonication/
nebulisation
Ligation of
sequencing
adaptors
Table 3. Main strategies proposed for target enrichment
2.2.1.2. Advantages and limits
The main advantages of the technology are related to its capability to process a large number
of samples in parallel. NGS technologies are time saving and lower the costs per patient, of
step 1 and particularly step 2 molecular analyses. But, they also have significant limitations
such as high error rates, enrichment of rare variants and large proportion of missing values,
as well as the fact that most current analytical methods are designed for population-based
association studies. With second generation sequencing, it is necessary to clonally amplify the
isolated targets in order to generate sufficient signal for detection during the sequencing run
generating clusters of many thousands of identical DNA targets. In addition, each NGS
platform generates different read lengths that range from short (e.g. 35 bases) to long reads
(over 500 bases). For a number of applications, including targeted re-sequencing, ChIP-Seq
and RNA-Seq, short reads are highly informative and adequate. Conversely, longer reads are
more suitable for de novo genome assembly, mapping of high homology regions (related gene
family and pseudogenes) and sequencing of repetitive DNA regions, such as introns. This is
an important consideration since short read length can make accurate assembly and alignment
computationally challenging.
For some clinical applications, as NGS produces massive amounts of data, their analysis and
interpretation are time-consuming, not trivial and a real challenge even if specific portions of
a genome is analysed.
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2.2.1.3. Bioinformatics software to analyse NGS data
Then, generated data are analysed by bioinformatics tools. Quality criteria such as confidence
or coverage are guarantees for optimal sensitivity and specificity of a sequencing run. Bioin‐
formatics analyses are frequently performed by using software developed by sequencers’
companies. The three steps include (1) base calling and quality score computation, (2) assembly
and alignment and (3) variant calling and annotation. Laboratories developed their own ‘in-
house’ pipeline mainly to apply filters allowing an easy focus on causing-mutations. Others
use free web resources to realign files including BWA (http://bio-bwa.sourceforge.net) or to
perform a new variant calling such as Samtools and GATK [21-23]. Others serve as Viewer
such as Integrative Genomics Viewer (http://www.broadinstitute.org/igv/). Galaxy website is
an integrative platform offering the possibility to view and process files generated by NGS.
Many databases, useful for variant annotation and sometimes inserted in others programs or
pipelines, are publicly available including the 1000 Genomes Project [24] and the dbSNP
database [25] (further described in part 3.1.1).
Many tracks are currently studied (i.e. improvement of bioinformatics tools, comparison of
NGS approaches between CF laboratories, development of databases including newly
detected NGS variants, publication of guidelines and definition of a diagnosis report model)
to make CF molecular diagnosis by NGS suitable for different clinical and familial cases.
2.2.2. Indications and choice of CFTR analysed regions
In the case of Mendelian diseases caused by mutations in a single gene, like CFTR in Cystic
Fibrosis, NGS sequencing of entire genome or exome is still useless and expensive. Collabo‐
rations between companies specialized in molecular diagnosis and academic laboratories
recently led to the establishment of new molecular diagnosis tools based on NGS. Combination
of (i) the enrichment of regions of interest by hybrid capture, circularization or Polymerase
Chain Reaction (PCR) and (ii) high throughput sequencing now allows time-efficient and
economical way to perform analyses. Use of NGS technology as a first intention is currently
set up in laboratories, which will soon question the CF diagnosis strategy as a tree. As shown
in Figure 2, in our actual CF molecular diagnosis strategy, NGS technology can be used instead
of ‘classical’ techniques for the detection of a panel of common mutations (step 1) or to analyse
the ‘CFTR exome’ (step 2). Technical manipulations are similar for both, but filters can be used
to focus on regions that contain mutations. Multiplicom® and Illumina® propose a locus
specific design to library preparation for molecular analysis of the ‘CFTR exome’. CE-marked
kits for in vitro diagnostic (CE-IVD) and efficient bioinformatics tools are commercialized. The
latter could be performed by in-house pipelines or subcontract on commercial firms (Sophia
Genetics®). SNV and indels are correctly detected (high specificity and sensitivity) and CNV
detection is now available for some amplicon-based methods.
Furthermore, in patients with definite CF clinical diagnosis (positive sweat test, CF clinical
features) and who carry no or only one CF mutation, step 3 analysis could be ultimately
proposed, in combination with the analysis of potential modifiers genes (see next section)
In literature, three studies reported NGS CFTR sequencing (Table 4) on CF patients, CF carriers
or controls samples [18, 26, 27]. Abou Tayoun and colleagues [26] first proposed a proof-of-
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concept for a ‘CFTR exome’ analysis by NGS on 79 samples. Target enrichment was performed
by PCR amplification (AmpliSeq Panel, Life technologies) and Sequencing on Ion Torrent
Platform (PGM®). Their sequencing offered minimal coverage of 100X (depending on the Ion
314 or 318 chip used). Two others studies realized sequencing of the whole CFTR locus (close
to 250 kb) including deep intronic CFTR regions (Figure 2, Step 3). Trujillano et al. [27] reported
the CFTR re-sequencing by hybridization capture on a custom NimbleGen SeqCap EZ Choise
array using HiSeq2000 (Illumina®) in a set of 92 samples. They highlighted the precise
characterization of breakpoints of seven genomic rearrangements in CFTR.
We proposed a complete CFTR gene sequencing of DNA samples from patients with a
confirmed CF clinical diagnosis but with an incomplete genotype [18]. Although large
unexplored intronic regions might contain few mutations (about 1%–3% of CF mutations), we
identified a new pathogenic mutation, which creates a pseudo-exon (Table 4). Moreover, we
compared hybridization capture and Long-Range PCR to target enrichment and used a small-
scale NGS platform for sequencing (GS Junior Sequencer, 454 Life Sciences®). Some promising
variants were then confirmed as deleterious by in vitro/ex vivo functional assays. However, for
most detected intronic variants, classification will be a long and difficult way. This approach
is currently under development for CF diagnosis.
Abou Tayoun et al., 2013 [25] Trujillano et al., 2014 [26] Bonini et al., 2015 [17]
Samples
57 subjects already genotyped
– 22 cell lines: 24 CF, 46 CF
carriers, 9 controls
92 subjects already genotyped: 45
CF, 27 CF carriers, 20 CFTR-RD
18 CF subjects in whom only one mutation had
identified
Study objectif Proof of concept of CFTRassay by NGS
Resequencing mutations
Validation technique
Identification of the second mutation
Comparison of two target enrichment
approaches
Sequencing protocol
Regions analyzed
All CFTR exons and 20bp of
all intron/splice sites (10
343bp)
All CFTR locus (208kb →  181kb
after masking repetitive DNA
elements)
All CFTR locus (250kb)
2.1million probes
(60-90pb)
36 overlapping
fragments (7.3-14.5kb)
Target enrichment Custom AmpliSeq panel (Lifetechnologies)
Hybrid capture: Custom
NimbleGen SeqCap EZ
Hybrid capture: Custom
NimbleGen SeqCap EZ
Long-Range -PCR
(LR-PCR) enrichment
Initial DNA quantity
per sample 20ng 500ng 750ng
Library preparation
2 separate primer pools (2x36
amplicons), end-repair,
ligation to adaptators,
quantification of Library
pooled bar-coded libraries
Clonal PCR
Sonication (Covaris
End-repair, A-tailing, ligation to
index adaptators (TrueSeq
protocol
CR), PCR amplification,
quantification of Library
(bioanalyzer), in-solution
hybridization
Nebulization; End-
repair, ligation to
adaptators,
quantification of
Library, Clonal
emulsion PCR
Nebulization; LR-
PCREnd-repair,
phosphorylation,
ligation to MID
adaptators,
quantification of
Library,
Clonal emulsion PCR
Sample Multiplexing
and cost 5 to 35 samples 8 to 24 samples No multiplexing 4 samples
NGS technology
200bp single reads
Ion 314TM (10Mb) or Ion 318
(1Gb)
Ion torrent Personal Genome
Machine (PGM)
2x100bp paired-end reads
HiSeq 2000 instrument (Illumina)
Single or Paired-end reads, up to 450 bp
GS Junior Sequencer (454 Life Sciences)
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Abou Tayoun et al., 2013 [25] Trujillano et al., 2014 [26] Bonini et al., 2015 [17]
Mapping Human genome Human genome (GATK pipelineand picard-tools)
Human Genome (454
Roche GS Junior data
analysis pipeline)
Chromosome 7
(454 Roche GS Junior
data analysis
pipeline)
Minimal coverage
Mean: 231X
99,7% covered by minimum 5
reads
40X
CFTR Sequencing statistics
Specificity 97% (22 on 23 mutations) 100% ND
Sensitivity 100% (23 on 23 mutations) 100% (122 on 122 variants) ND
Reproducibility 100% (56 on 56 variants in 3independent runs) 100% (8 on 8 variants) ND
Bioinformatics tools
CNV
Depth-Of-Coverage tool from
the Genome Analysis ToolKit
(GATK)
--> Log2 ratios < -0.7: deletion
Pindel; Conifer; PeSV-Fisher
5 large deletions, 1 duplication and
1 genomic rearrangement
ND
SNV 7 variants per sample onaverage
115 SNV + 28 InDels on average
per sample
197 variants on average per sample (118 in
introns)
Variant identification
and calling Not notified
Variant prediction tools: GATK
Unified Genotyper, samtools
mpileup, SHORE
Reference Mapper
Mutalyzer
SeqNext (JSI medical systems)
Variant filter
Min coverage: 20 reads
Threshold: 25% reads
Both strands
GATK Variant filtration (MQ<30.0;
QUAL<25.0; QD<4.0; DP<5;
DP<2000; GQ<15)
GATK Combine Variant
Threshold 30% of reads
Heterozygous: Read support: 30-65%
Homozygous >70%
Databases
Variant frequency > 1%
dbSNP
Exome Variant Server
CFMDB
CFTR2
1000 Genomes project
dbSNP
Exome Variant Server
CFMDB
CFTR2
1000 Genomes project
dbSNP
In silico analysis SIFTMutation Taster
Annovar
SIFT, PolyPhen2, PhyloP, Mutation
Taster, phastCons
UCSC Genome Browser
Annovar, HSF, MaxEnt, NNSplice, SIFT,
Polyphen2, PhyloP, UCSC Genome Browser,
Ensembl, MutationTaster
Performance
Diagnostic rate ND 98.91% 88.9% (16 / 18)
Particular cases
False positive c.2052del
(2184delA)
Sanger sequencing to
determine the c.
1210-34TG(11-13)T(5-9)
haplotype
In-house script to determine the c.
1210-34TG(11-13)T(5-9) haplotype
False positive c.2052del (2184delA)
Sanger sequencing to determine the c.
1210-34TG(11-13);-12T(5-9) haplotype
Advantages Robust, specific, limitednumber of VUCs
Breakpoints of large genomic
rearrangement accurately
determined
LR-PCR more adapted for complete gene
resequencing
New intronic mutations identified
Limits
SINE/LINE repeats
(amplification and mapping)
Homopolymer stretches
(Sequencing)
GC rich genomic segments (target
enrichment)
Errors in index tags (sequencing)
SINE/LINE repeats (amplification and
mapping)
Homopolymer stretches (Sequencing)
Uncaptured region in intron 3
Table 4. Comparison of three NGS strategies for CFTR sequencing
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2.3. Other loci
With the perspectives of high throughput molecular diagnosis in genetics laboratories, CF,
CFTR-RDs and CF-like diseases could be simultaneously explored in patients using NGS.
Various gene panels could be investigated according to patients’ phenotypes. Therefore, NGS
approaches could contribute to (i) identify and confirm the implication of modifiers genes and
(ii) improve molecular diagnosis of atypical Cystic Fibrosis, CFTR-RDs or CF-like diseases.
Several sequence changes located in the so-called ‘modifier genes’ have been associated with
progression of lung disease in CF patients. A decrease of pulmonary function measured by
FEV1 (the forced expired volume after 1 s of blowing out) was associated with SNVs in EDNRA,
ACER, IFRD1, IL8, MUC5AC and TGF-β1 genes. Haplotype 8.1 and variants in MBL2 gene were
related to Pseudomonas aeruginosa colonization [28, 29]. SNVs in SNAP23, PPP2R4, PPP2R1A and
KRT19 were recently associated with a decrease of lung function. Interactions between CFTR
and these altered proteins may modify CFTR trafficking and membrane stability and there‐
fore modify phenotype of CF patients [30]. Moreover, changes in other modifier genes were
suspected to have an effect on intestinal obstruction (DCTN4, ADIPOR2 and MSRA genes), CF-
associated diabetes (TCF7L2 gene) or liver disease (SERPIN1A1) [31].
CFTR-Related disorders  comprise congenital  bilateral  absence of  vas deferens (CBAVD),
pancreatitis, diffuse bronchiectasis and nasal polyposis. Classically, two CFTR mutations (a
severe and a mild mutation or two mild mutations) are found in well-characterized CBAVD
patients [32]. In addition, Sharma et al. reported 2 SNVs on TGF-β1 and ENDRA genes associat‐
ed with urogenital anomalies [33]. Chronic pancreatitis is caused by CFTR variations in some
cases, and mutations in CTRC, PRSS1, PRSS2 or SPINK1 are also involved and must be analysed.
The implication of CFTR in diffuse bronchiectasis or nasal polyposis is more controversial [34];
variants in other genes were previously reported as possibly causative. However, the identifi‐
cation of mutations in other genes with sufficient significance remains difficult and needs large
patient cohorts. In fact, in airway tract diseases, the influence of environment (pollutants, drugs/
therapy and way of life) complicated the achievement of unbiased studies. Nevertheless, the
hypothesis of oligogenism is supported by a study that reported mutations in ENaC channel
genes (SCNN1A, SCNN1B, SCNN1G) or SERPIN1A1 in CF-like patients (borderline sweat-
test and suggestive CF clinical features without two CFTR mutations) [35].
Finally, a pleiotropic effect of SLC26A9 on meconium ileus, pancreatic damage and lung disease
has been identified [36], as well as SLC9A3 for meconium ileus and lung disease and SLC6A14
for meconium ileus and both lung disease and age at first P. aeruginosa infection [37]. Thus, the
existence of pleiotropic effect of modifier genes on CF evolution may encourage the develop‐
ment of new therapeutic targets with multi-organ benefits.
3. Functional characterization of CFTR sequence variations
To provide appropriate diagnosis and prognosis to CF patients and also appropriate genetic
counselling to families, the impact of variants identified by the techniques detailed above has
to be functionally characterized.
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Some variants such as frequent mutations (found in more than 1% of CF mutated alleles),
nonsense or frameshift mutations are readily classified as pathogenic mutations. However, the
frequent identification of rare sequence alterations of unknown pathogenicity (VUCS, VUS)
substantially complicates test interpretation. Moreover, their number will increase with the
diffusion of NGS technologies. To facilitate classification of these variants, CF laboratories have
to combine several tools like central mutation databases or CFTR locus specific databases, in
silico prediction tools and ex vivo/in vivo functional analyses [38, 39].
3.1. Epidemiological data and locus specific databases dedicated to CFTR
3.1.1. Core or central mutation databases
Their goal is to collect all sequence variations detected in all genes and to describe each
mutation briefly. These databases are used to assess the frequency of a variation (minor allele
frequency (MAF) lower or higher than 1%) in the general population (i.e. unaffected individ‐
uals). Since a MAF higher than 1% reflects a low probability for the variant to be pathogenic,
such data may be highly informative for the interpretation of variants.
3.1.1.1. The National Center for Biotechnology Information (NCBI) short genetic variations database
dbSNP
dbSNP [25] is the most comprehensive directory of single nucleotide variations. It catalogues
short variations in nucleotide sequences from a wide range of organisms. Genetic Variations
may be common, thus representing true polymorphisms, or they may be rare. Some of these
rare human entries have additional information associated with them, including disease
associations, genotype information and allele origin, as some variations are somatic rather than
germ-line events. Genotypes and allele frequencies information for various populations from
different studies, including data form the HapMap project, are also available.
3.1.1.2. Databases specifically collecting data from NGS projects
1000Genomes [24] aimed to find most genetic variants that have frequencies of at least 1% in
samples from five populations: East Asian, South Asian, African, European and American
ancestries. As in dbSNP, genotypes and allele frequencies information are available for a large
number of variants [40].
Exome Variant Server [41] is a database that collects data of the NHLBI GO Exome Sequencing
Project (ESP). This project aimed to discover novel genes and mechanisms contributing to
various disorders by sequencing the protein coding regions of the human genome (i.e. exome)
using NGS technology. As the CFTR gene is widely studied, this tool would not be of added
value compared to dbSNP and 1000 Genomes.
3.1.2. Locus Specific Databases (LSDBs) dedicated to CFTR
LSDBs are now recognized as the best mode of collecting and curating lists of mutations related
to human genetic diseases [42]. They compile in a single bioinformatics tool disease-causing
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and non-disease-causing sequence variations identified by genetics laboratories in families
with a history of a given Mendelian disease. The most sophisticated ones integrate clinical and
biological data, information on the geographic and/or ethnic origin, frequency of variations in
the general population, mutation hot spots and all useful information for diagnosis, prognosis
and the evaluation of genotype/phenotype relationships [43].
Here we choose to detail three LSDB dedicated to CFTR that provide complementary infor‐
mation for the interpretation and the characterization of variants identified in diagnostics
practice.
3.1.2.1. Cystic fibrosis mutation database
The Cystic Fibrosis Mutation Database (CFMDB) [44] also called ‘CFTR1’ is an open access
database dedicated to the collection of sequence variations in the CFTR gene for the interna‐
tional CF genetics research community. It was initiated by the Cystic Fibrosis Genetic Analysis
Consortium (CFGAC) in 1989 and is maintained by the Cystic Fibrosis Centre at the Hospital
for Sick Children in Toronto. CFMDB allows the direct submission of new variants by
laboratories, by filling out an on- line standardized form with the possibility to detail pheno‐
typic data, genotype (i.e. other variants identified in patient) or epidemiological data. The key
point of this database is to collect the largest number of CFTR sequence variations identified
in patients, relatives and partners. On the other side, because the submission procedure applies
only to the initial report of each variant, CFMDB does not provide frequency data, available
with the two other databases described below. Finally, contributors do not always follow
HGVS recommendations and a same variant can be reported by several laboratories under
different names, possibly leading to misinterpretation or misreporting in diagnosis reports.
3.1.2.2. Clinical and functional translation of CFTR database CFTR2
CFTR2 [45] is a website designed to provide information about specific CF mutations to
patients, researchers and the general public. For each mutation included in the database, it
provides information about whether a given mutation causes cystic fibrosis when combined
with another CF-causing mutation and clinical and biological information (sweat chloride,
lung function, pancreatic status and pseudomonas infection rates) in patients carrying the
mutation. A specific section for health practitioners and scientists provides more in-depth and
research-related information.
The goal of the CFTR2 project is to categorize all mutations seen in CF patients as disease-
causing (always resulting in CF when combined with another CF-causing mutation), neutral
or mutation of varying clinical consequences (CF and CFTR-RD). Mutations that have not been
fully analysed are considered of unknown clinical significance.
The major advantages of CFTR2 are (i) the collection of detailed clinical characteristics on large
cohorts of individuals [46] that provide useful information related to a given genotype, and
(ii) results of functional testing that are key arguments for their final interpretation [47].
However, this database only collects clinical and genetic data of CF patients (from national
registers) that can lead to a bias of phenotypic spectrum assessment of several mutations
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considered as CF-causing mutations while they were also reported in CFTR-RD patients in
trans of other CF-causing mutations.
3.1.2.3. The French molecular database CFTR-France
CFTR-France [48] has been developed since 2012 with the aim to collect, store and process any
category of variants identified in the CFTR gene, thanks to the collaboration of nine French
laboratories with high expertise in the molecular analyses of this gene. Its specificity is to
compile and annotate any category of variations (disease-causing, non-disease-causing and
variants of unknown clinical significance) that have been identified by collaborators in patients
affected with CF or CFTR-RD, in foetuses with abnormal ultrasonography (e.g. echogenic
bowel), newborns with pending or inconclusive diagnosis and asymptomatic individuals
carrying at least one sequence variation on each CFTR gene (i.e. carrying two variations in
trans). The database includes the main clinical data of these individuals, genetic information
from familial segregation studies and various variant annotations (frequency in patients and
controls populations, sequence homology, predicted or experimentally assessed functional
impact, etc.), allowing the analysis of genotype/phenotype relationships.
Thus, CFTR-France, by collecting all phenotypes, reflects the phenotypic spectrum of a large
number of mutations. It also reports mutations in complex alleles with association frequencies
(related to all individuals recorded in the database), and gives the up-to-date HGVS nomen‐
clature of mutations.
Data collected in CFTR-France are provided by level 2 (specialised) and reference laboratories,
so that patients analysed only by level 1 laboratories (searching for the most common muta‐
tions) are not included in the database.
Note: Access to CFTR-France is currently restricted to collaborators. A public access program
is in progress for the medical and scientific community and for patients and families.
3.2. In silico prediction analyses
3.2.1. Variants located in exons and exon-intron boundaries
3.2.1.1. Prediction tools for the assessment of the impact on protein
Prediction methods of amino acid substitutions use protein sequence, structure and/or
annotation. Disease-causing mutations that affect protein function tend to occur at evolutio‐
narily conserved sites and/or at key positions in protein structure. Multiple sequence align‐
ment of orthologous sequences reveal what positions have been conserved through evolution,
and these positions are supposed to be important for protein function. Annotation can enhance
prediction for variants located in structurally and functionally important domains, but this
information is often sparse.
The issue of the efficiency of prediction tools in assessing possible pathogenicity of missense
variants in the CFTR gene is of major interest, since they constitute the vast majority of VUS
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identified in patients. Diagnostics laboratories frequently use those tools and particularly in
problematic situations. Unfortunately their performance has not been clearly established and
results (i.e. score of pathogenicity) may be discordant for a given variant.
Predictions of the impact of non-synonymous substitutions in CFTR are mainly based on
multiple sequence alignment of orthologous sequences. Indeed, even if a partial 3D model of
the CFTR protein has been established [49, 50], prediction tools do not take into account these
elements in the final ‘score of pathogenicity’. It is classically recommended to use several
prediction tools to obtain concordant predictions that could be considered for variant inter‐
pretation.
Table 5 summarizes bioinformatics programs classically used by diagnostics laboratories
[51-53] and the new software SuSPect [54].
Method and Web site Algorithm Output
PolyPhen 2 [54] Sequence conservation, structure to model position ofamino acid substitution, and SWISS-PROT annotation
Score ranges from 0 to a positive
number, where 0 is neutral, and a high
positive number is damaging
SIFT [55]
Sequence homology:
scores are calculated using position-specific scoring
matrices with Dirichlet priors
Score ranges from 0 to 1, where 0 is
damaging and 1 is neutral
Align GVGD [56]
Multiple sequence alignments to characterise the
biochemical properties (composition, polarity and
volume) of the observed amino acids at each position
The prediction classes form a spectrum
(C0, C15, C25, C35, C45, C55, C65) with
C65 most likely to interfere with
function and C0 least likely.
SuSPect [57]
Sequence-, structure*- and systems biology-based
features to predict the phenotypic effects of missense
mutations.
Algorithm trained using VariBench (contains
information for experimentally verified effects)
*Structure-based comparison with other ABC transporters
Table of scores from 0-100, colour-
coded according to predicted
deleteriousness (blue=neutral,
red=disease-causing).
A score of 50 is recommended as a cut-
off between neutral and disease-causing
variants
Alamut© [58]
Commercial software (Interactive
Biosoftware)
Databases: RefSeq, dbSNP, Uniprot, InterPro, UCSC
Genome Browser Database, PubMed, Ensembl.
And
Automated access to on-line prediction tools:
PolyPhen2, SIFT, Align GVGD
Access to splicing prediction tools (detailed in Section
III.2.1.2.)
“Alamut Batch”
High-throughput annotation software for NGS
analysis
Summarized report of the results of
different prediction tools, according to
their output format
Designed for intensive variant
analysis workflows
Table 5. Bioinformatics tools for the prediction of amino acid changes: websites, characteristics and output format
[55-59]
A recent work has emphasised the importance of sequence alignments on the performance of
prediction tools [60]. The authors constructed custom multiple sequence alignments called
phenotype-optimized sequence ensembles (POSEs) that was tested on a training set of CFTR
mutations.
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A previous work already suggested that providing SIFT or PolyPhen-2 with custom align‐
ments increased their performance relative to the default alignments employed by the
algorithms [61]. This could explain that, if Alamut© is a highly interesting tool with its ease of
use, some predictions obtained by using each tool separately with a custom algorithm could
differ from Alamut© results (obtained with default alignments).
3.2.1.2. Prediction tools for the assessment of the impact on pre-mRNA splicing
Splicing mechanisms comprise exon recognition within large pre-mRNA molecules and the
precise removal of flanking introns. Three elements constitute the core splicing signals: the
intronic branch point, the acceptor site (or 3’splice site), including an inconstant upstream
polypyrimidine tract (PPT), and the donor site (or 5’ splice site). These core human splice site
motifs contain only a part of the information that defines exons, whereas the rest corresponds
to less conserved splicing regulatory elements. The latter are located within the exon or
flanking introns, promoting or inhibiting exon recognition through exonic/intronic splicing
enhancers (ESE or ISE) or silencers (ESS or ISS), respectively (Figure 3).
Figure 3. A schematic of key splicing motifs and regulatory elements. Adapted by Le Guédard-Méreuze S. from Wang
and Burge, 2008 [62, 63].
Many bioinformatics tools have been developed to predict which splicing modification is the
most probable for a given sequence variation — exon skipping, cryptic splice sites activation,
use of de novo splice sites — or if the variant may be considered as neutral regarding its impact
on splicing. Most algorithms were developed based on biostatistical and experimental analyses
of information contained in the genomic sequence. They provide a score depending on the
strength of the considered splice site. Indeed, the strength of splicing motifs is a key parameter
to predict the impact of a sequence variation. Performance of these tools has been widely
studied by comparing the results of predictions with experimental assays for various genes
including CFTR [39, 63-66]. In 2012, Houdayer and collaborators performed a large-scale study
of VUCS in BRCA genes in order to assess the performance of six prediction tools [67]. This
work provided guidelines for the proper use of these tools and for the interpretation of
prediction results.
Table 6 summarizes principle and main characteristics of the most ‘popular’ bioinformatics
programs and ASSEDA, a recently developed program [68-73].
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Method and Web site Algorithm Output
MaxEntScan [72]
Based on a Maximum Entropy Model
(MEM):
Modelling the sequences of short sequence
motifs such as those involved in RNA
splicing which simultaneously accounts for
non-adjacent as well as adjacent
dependencies between positions.
Human Splicing Finder (HSF) [73]
Associates weight matrix model
(WMM) and
Maximum Entropy Model (MEM)
Consensus splice sites
HSF (WMM): Quantification of the relative
likelihood of candidate splice site sequence to
show coincidence with consensus sequence
Numerical Score
(0-100)
MaxEnt (MEM): Statistical approach
representing the least biased approximation for
the distribution of sequence motifs, from
available data (real and decoy splice sites).
Incorporates local adjacent and non-adjacent
position dependencies
Numerical Score
(0-10)
cis-regulatory elements
ESEfinder*
RESCUE-ESE*
Predicted PESE AND PESS Octamers from
Zhang & Chasin
*See Prediction tools for cis-regulatory
elements
See Prediction tools for cis-regulatory
elements
NNSplice [74]
Machine learning approach that recognizes
sequence patterns once it is trained with sets
of DNA sequences encompassing authentic
and decoy splice sites.
Based on a hidden Markov Model (HMM):
Incorporates local adjacent position
dependencies
Score between 0 and 1
Automated Splice Site and Exon
Definition Analysis (ASSEDA) [75]
Restricted access: registration required
Analyses splicing mutations according to
changes in total exon information:
information content of a spliced exon from
the cumulative contributions of sequences
recognized by the spliceosomal machinery
and the distribution distances separating
binding sites within the same exon.
∆Ri,total values (differences in probability of
relative inclusion or exclusion of the wild
type and mutated exon in mature mRNA)
Prediction tools for cis-regulatory elements
ESEfinder [76]
Prediction of SR protein specific putative
ESE, based on an in vitro SELEX approach
dependent on addition of individual SR
proteins
ESE motif score
RESCUE-ESE [77]
(Relative enhancer and silencer
classification by unanimous
enrichment)
Statistical approach based upon different
distribution of hexamers in exons and
introns with different properties (e.g. weak
and strong splice sites)
Z-score
(Highlights extremely over- or under-
represented hexamers)
Table 6. Main characteristics of several Splicing prediction tools [74-79]
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It is important to note that consequences on splicing of exonic synonymous and non-synony‐
mous CFTR variants must be assessed, as suggested by recent of experimental studies [39, 80].
3.2.2. Deep intronic variants
The examples of insertion of intronic sequences called pseudo-exons (or cryptic exons) in
mature transcripts of various genes are becoming ever more numerous and their role in human
diseases has been largely demonstrated. We saw in section 2.2 that NGS strategies currently
allow scanning of CFTR deep intronic regions [18], resulting in a growing number of new
identified deep intronic variants.
Bioinformatics tools described above, which assess the impact of variants on splicing, can also
be used to evaluate deep intronic mutations. We tested these algorithms on mutations
identified in CF patients after NGS sequencing of the entire CFTR locus and they showed
satisfactory results [18]. Indeed, prediction tools allowed the selection of possible disease-
causing mutations (i.e. predicted impact on splicing by inclusion of pseudo-exons) and
predictions were confirmed by in vitro functional studies using minigene constructs (see
section 3.3.1.1) and by direct analysis of aberrant transcripts from nasal epithelial cells of
patients (see 3.3.2.1).
3.3. In vitro/ex vivo functional analyses
3.3.1. Cell lines transfection experiments
The type of cells used for transfection depends on the tissue that is studied and the clinical
context. Pulmonary (BEAS-2B, A549, Calu-3) or intestinal/colic (CACO-2, T84) immortalized
cells (by SV40 or carcinoma) contain an appropriate concentration of transcriptional and
splicing factors for CFTR protein synthesis. Cells stably transfected with mutated CFTR can
also be used (CFBe41o-, CFPAC-1). Stable expression is usually obtained by lentivirus
transduction and transient transfection by chemical agent (Polyfect, interferin). In this case,
the endogenous CF molecular and cellular context (inflammation) should also be considered.
3.3.1.1. Splicing assessment
Minigenes are autonomic cyclic entity containing promoter and exons and are produced by
clonal amplification in bacteria [81, 82]. They contain a genomic segment from the gene of
interest (here CFTR) that includes exon and flanking intronic regions (length can range from
ten to thousands of nucleotides, an average of 300 bp) or only intronic regions in the case of
evaluation of potential creation of a pseudo-exon. To determine whether a mutation is
responsible for altered splicing, minigenes can also include cis-regulatory elements if affected
(ESE, ESS, ISE or/and ISS) [83]. These regions of interest are framed by two invariable exons,
which are part of the system. Every assay of transfection in cell lines compares the wild-type
and mutated (through directed mutagenesis) constructs [84]. All CFTR exons are needed to
produce a mature and functional protein. Thus, a modification of transcript in the in vitro
system suggests that the assessed CFTR change has a deleterious effect on exon splicing. An
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ever-increasing number of mini-gene studies have been performed to assess the pathogenicity
of CFTR variants [39, 60, 80, 84]. This strategy, despite its limitations, is of high interest in the
overall strategy for the characterization of rare sequence variations.
3.3.1.2. Expression vectors for the quantification of mRNA, protein or CFTR-specific chloride
conductance
Full-length CFTR cDNA is classically inserted in expression vector system (e.g. pcDNA3 or p-
Tracer) upon a promoter that may be drug-activated (G418, tetracycline or doxycycline-
activation). To assess point variants or small indels, directed mutagenesis is carried out
(usually QuikChange Mutagenesis kits®, Agilent Technologies). To assess molecular conse‐
quences of large rearrangements concerning one or more exons, a truncated CFTR cDNA can
be inserted in the expression vector [85-87]. Transient or stable transfection can be performed
in eukaryotic cells (describe in III.3.1. section). 3-HA tag (in the fourth loop of CFTR) can be
introduced to easily visualize protein expression. Then, measurement of mRNA expression
and evaluation of function and localization of the CFTR protein can be performed for each
alternative transcript construct, compared to wild-type.
Automated real-time RT-PCR allows the relative straightforward quantification of mRNA
transcripts with specific primers and appropriate reference genes for normalization. mRNA
level informs about future protein quality and quantity.
Protein assessment consists in the implementation of complementary experiments for protein
quantification, evaluation of its maturation or its cellular localization. Main techniques are
detailed below. The effect of variants on CFTR expression and maturation is assessed based
on the detection of immature (core-glycosylated, B band, ~150-kD) and/or mature (additional
glycosylation in the Golgi, C band ~170-190 kDa) CFTR forms by immunoblotting. Long-term
pulse-chase experiments can provide additional information on the lifetime of CFTR on
cellular compartments [88]. Immunocytochemical assays (Immunofluorescence (IF) based) can
highlight the cellular localization of the CFTR protein. However, most difficulties noted in IF
experiments relate to non-specific antibody staining and the effect of sample processing on
characteristics of cell development. Moreover, confusion between cell surface (where CFTR is
active) and subsurface (where it would not) may occur. Therefore, more sensitive and specific
antibodies as well as co-localization assays with other cell surface markers (such as β-tubulin
or WGA) are needed. Finally, this remains a qualitative or semi-quantitative method.
CFTR function and activity, i.e. CFTR-specific chloride conductance, can be determined by
patch-clamp electrophysiology, halide selective electrode technique, radioisotope efflux
assays and by fluorescence-based halide efflux measurement. The use of a CFTR-activating
appropriate drug (such as forskolin, isobutylmethylxanthine (IBMX), isoproterenol, terbuta‐
line, genistein, adenosine, etc.) or ATP followed by specific CFTR inhibitor CFTRinh-172
permits CFTR-dependant or independent chloride transport, respectively. To date, the easiest
approach developed consists in Iodide efflux based on fluorescence measurement. YFP
fluorescence is dependent on YFP expression levels and iodide concentration. Compared with
conventional plate-bound CFTR functional assays, the flow cytometric approach can be used
to study CFTR function in cell suspension. It may be further adjusted to study CFTR function
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in heterologous cell populations using cell surface markers and selection of cells that display
high CFTR function. Technical limitations include the need to perform this assay in specialized
centres (using expensive imaging equipment).
All these methods offer the possibility to evaluate the functional consequences of molecular
abnormalities on CFTR and finally improve the classification of variants.
3.3.2. Ex vivo CF patients’ cells assays
3.3.2.1. Analyses on primary airway cells and tissues
Characterization of CFTR molecular defect can partially be performed directly after biopsies
of tissues that show sufficient CFTR expression. Nasal or lung airway epitheliums are optimal.
These tissues are accessible by minimally invasive interventions and display an endogenous
expression of CFTR transcripts and protein. Moreover, nasal and bronchial epitheliums show
the same cellular composition (ciliated, goblet, columnar and immune cells) although ratios
differ slightly [89]. Since quantification and detection of aberrant splicing and quantification
or localization of proteins are possible in human tissues, information that they bring is crucial
to assess the effect of variants and to propose a functional classification. However, this
approach has its limitations and requires other functional assays to perform large-scale
genotype–phenotype correlation studies. In addition, especially for nasal tissue, the low
quantity of cells collected (out of 500.000 cells per brushing) only allows ‘one-shot’ tests and
hinders mechanistic assays. Moreover, highly variable CFTR expression in heterogeneous cell
types, in healthy individuals and in p.Phe508del homozygous patients has been described,
varying from 0 to 100% [90]. Other genetic (see below) or environmental parameters could also
modify CFTR expression levels.
3.3.2.2. Ex vivo culture of primary airway cells
Culture of primary cells from CF patients can be performed with brushed nasal or bronchial
cells after biopsies. Wild-type endogenous CFTR protein is expressed at the apical mem‐
brane of  polarized cells.  Therefore,  in vitro  monolayer culture seems no longer adapted.
Obtaining polarized cells is promoted by air–liquid interface culture (ALI), proposed since
the 2000s,  by an ex vivo  system of collagen-coated porous membrane on which cells  are
platted  after  a  phase  of  monolayer  amplification  or  directly  after  nasal  brushing.  Basal
adherent cells differentiate in all airways epithelial cell types, which organize into a pseudo-
stratified epithelium [91].
This model offers the opportunity to perform functional assays described above to determine
CFTR dysfunction. Molecular defect induced by a specific mutation can be qualitatively
determined if the cell donor is homozygous for this mutation.
Technical limitations such as bacterial or fungi contaminations or absence of adherence
complicate culture of cells obtained from CF patients. Moreover, further studies are needed to
determine if extrapolation is possible between observations in primary cells directly after
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brushing and after several weeks in culture media, particularly for quantitative level assess‐
ment.
3.3.2.3. Intestinal current measurement (ICM)
ICM was developed as a research tool to assess CFTR function in the 1990s and has been used
as a diagnostic test since the early 2000s [92, 93]. At least four superficial rectal biopsies per
patient, obtained by suction, are needed and mounted on adequate tissue sliders. ICM consists
in blocking epithelial sodium channels by amiloride and stimulates cAMP-mediated CFTR-
depending chloride transport in a chloride-free solution with forskolin or IBMX. Cholinergic
chloride transport and histaminic reaction were also evaluated and the sum of the response
∆Iscforskolin/IBMX+carbachol+histamine appears to be the best parameter to evaluate CFTR function by ICM,
but reference values and ranges have not been established. This combination of ionic responses
discriminates patients with CF from healthy subjects but not CF patients with pancreatic
insufficiency (PI) or sufficiency (PS). ICM can detect a loss of CFTR function above 80%,
therefore CF carriers and CFTR-RD patients may not be identified by this method. Moreover,
mild mutations could result in a false-negative ICM.
ICM is not altered by secondary damage on tissue and thus better reveals the primary CFTR
dysfunction (compared with nasal potential difference, see below). A new functional CFTR
assay using primary CF intestinal organoïds derived from patients and cultured in vitro may
offer new tools to screen for therapy [94].
Finally, setup and maintenance of dedicated equipment by experienced and trained staff limits
its use.
3.3.3. In vivo biomarkers assays of CFTR function
Sweat chloride Test (ST) and Nasal potential difference (NPD) measurement are used as
diagnostic tests for CF. In atypical clinical context these in vivo tests can give additional
arguments to further explore the CFTR locus (cf. Figure 2 that describes the molecular
diagnostics step-by-step strategy). Furthermore, they provide complementary information for
the interpretation of CFTR variations.
ST higher than 60 mmol/L is the ‘gold standard’ and discriminates between healthy and typical
CF. Sweat electrolytes are higher in the most severely affected and are lower in those with mild
mutation, who have partial rescue of channel function [95-97]. There are two major advantages
for the use of sweat test in the evaluation of the CFTR mutation severity: (i) stability of the
measure throughout life and (ii) non-invasive way of measurement which maintains skin
integrity. Indeed, sweat electrolytes levels reflect the primary defect on the CFTR protein and
do not highlight secondary consequences of its absence or dysfunction on affected organs.
Furthermore, a new means for assessing the secretory function of CFTR has been recently
developed based on β-adrenergic-mediated sweating. This method provides a unique
evaluation of the purely secretory function of CFTR in vivo. It has been shown to be more
sensitive in individuals carrying mutations that commonly exhibit normal or borderline sweat
chloride rates, such as c.3718-2477C>T (legacy name: 3849+10kbC>T) [98].
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The transepithelial NPD measurement estimates the net ion conductance across the nasal
airway epithelium and indirectly measure CFTR activity. Sodium conductance is determined
after amiloride perfusion (Na+). NPD parameters discriminate CF and CFTR-RD phenotypes
and a correlation between NPD and disease severity has been shown [99], although there is
an overlap in subjects with mild phenotype [97]. However, other sources of phenotypic
variability (modifiers genes or environment) and technical limitations (i.e. maintenance of
dedicated equipment and trained personnel) contribute to the inconsistencies of NPD across
genotype-phenotype correlation studies. CFTR expression and NPD response can also be
modified if nasal epithelium is affected by rhinosinusitis, polyposis or exposure to smoking
[100]. However, despite the difficulty of setting up this technique, NPD assessment could be
used as a complementary step to support CFTR dysfunction in inconclusive clinical cases and
then to confirm the deleterious effect of CFTR variants identified in these patients.
4. Conclusion
New issues are emerging from the use of NGS technology in CF molecular diagnosis. On one
hand, NGS approaches offer new possibilities by multiplexing samples and provide a wider
coverage of the CFTR locus including deep intronic regions. NGS assay design can also include
additional modifiers genes [31]. On the other hand, molecular diagnoses in emergency contexts
challenge the possibility of sample multiplexing, and the increased number of VUCS will
require complex functional analyses. However, as tools described above are constantly
improving, the knowledge about CFTR variations is rapidly expanding, allowing geneticists
and clinicians to provide patients with high quality information and adequate genetic
counselling. Finally, the functional characterization of CFTR variations will provide rationale
for a personalised medicine strategy driven by patients’ genotype in the very near future.
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